Publications, posters, and abstracts
MVP staff and partners have been involved in the publication of scientific papers, and they regularly attend national and international conferences that address issues related to meningitis, epidemiology, and vaccine development. Some of the publications, posters, and/or abstracts not listed in our Research and Development section are listed below.
The PATH Vaccine Resource library provides additional information on meningococcal meningitis, meningococcal vaccines, epidemiology, and vaccine research.
Publications
Brooke S, Harner-Jay CM, Lasher H, Jacoby E. How public-private partnerships handle intellectual property: the PATH experience. In Krattiger A, Mahoney RT, Nelsen L, et al, eds. Intellectual Property Management in Health and Agricultural Innovation: A Handbook. Oxford, UK: MIHR; 2007:1755–1763. (pdf 261 kb).
Colombini A, Bationo F, Zongo S, et al. Costs for households and community perception of meningitis epidemics in Burkina Faso. Clinical Infectious Diseases. 2009;49(10):1520–1525. View abstract.
Findlow H, Plikaytis B, Aase A, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clinical and Vaccine Immunology. 2009;16(7):969–977. View abstract.
Foschiatti M, Hearshaw M, Cescutti P, Ravenscroft N, Rizzo R. Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A. Carbohydrate Research. 2009;344(7):940–943. View abstract.
Jodar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. Lancet. 2002;359(9316):1499–1508. View abstract.
Kieny M-P, LaForce M. The promise of conjugate vaccines for Africa. Vaccine. 2007;3(25) Suppl 1:A108–110. View abstract.
Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007; 3(25) Suppl 1:A101–107. View abstract.
LaForce FM, Konde K, Viviani S, Préziosi M-P. The Meningitis Vaccine Project. Vaccine. 2007;3(25) Suppl 1:A97–100. View abstract.
LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine. 2009;24(27) Suppl 2:B13–19. View abstract.
Lee C, Kuo W, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine. 2009; 27(5):726–732. View abstract.
Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: A demonstration project. Journal of Health, Population, and Nutrition. 2004;22(3):275–285. View abstract.
Thomson M, Molesworth A, Djingarey M, Yameogo K, Belanger F, Cuevas L. Potential of environmental models to predict meningitis epidemics in Africa. Tropical Medicine & International Health. 2006;11(6):781–788. View abstract.
World Health Organization (WHO). Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience (pdf 537 kb). Weekly Epidemiological Record. 2005;37(80):313–320.
World Health Organization (WHO). Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. 2006;BS/06.2041 (pdf 442 kb).
Posters
Badolo O, Tiendrebeogo E, Novak R, et al. Surveillance of meningococcal disease in Burkina Faso. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P234 (pdf 4.21 mb).
Caugant D, Tamboura B, Tapia M, et al. Lessons from meningococcal carriage studies in West Africa. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 131 kb).
Caugant D, Tamboura B, Tapia M, et al. Carriage of Neisseria meningitidis in 2–29 years old in Mali, Senegal, and The Gambia. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P168 (pdf 4.21 mb).
Djingarey M, Noazin S, Préziosi MP, et al. A 20-year retrospective analysis of epidemic meningitis surveillance data in Burkina Faso, Mali, and Niger. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P166 (pdf 4.21 mb).
Djingarey M, Perea W, Bertherat E, et al. Implementation of standard operating procedures for enhanced meningitis surveillance in 13 countries of the African meningitis belt from 2003 to 2008. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P231 (pdf 4.21 mb).
Findlow H, Borrow R, Sow S, et al. Meningococcal serogroup C and W135 immunological hyporesponsiveness in African toddlers. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 4.02 mb).
LaForce M. Nearing success: The development of an affordable group A meningococcal conjugate vaccine to eliminate epidemic meningitis from Africa. Oral presentation at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. O62 (pdf 4.21 mb).
Ravenscroft N, Hearshaw M, Martino A, et al. Physicochemical and immunological characterization of the drug product (final lot) of a meningococcal group A conjugate vaccine. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P101 (pdf 4.21 mb).
